A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China

Summary

The CARDIAC trial is a prospective, parallel, open-label cluster randomized trial that aims to determine the effectiveness of a coronary computed tomography angiography (CTA)-guided intensive intervention strategy, as compared with standard care, on reducing the incidence of major adverse events (MACE) at 18 months among high-risk cardiovascular populations in rural China. An extended observational follow-up at 36 months will be conducted to further evaluate the effect on long-term clinical outcomes.

Conditions

• Coronary Artery Disease

Interventions

DIAGNOSTIC_TEST

CTA-guided Intensive Intervention Strategy

Intensive intervention strategies based on the result of coronary computed tomography angiography

OTHER

Comprehensive Intervention Strategy

Comprehensive intervention strategies based on guidelines and expert consensus

Sponsors & Collaborators

• Daqing Oil Field Hospital

  collaborator OTHER

• Heilongjiang Provincial Hospital, China

  collaborator UNKNOWN

• The First Hospital Of Qiqihar

  collaborator UNKNOWN

• Mudanjiang Cardiovascular Hospital, China

  collaborator UNKNOWN

• Hongqi Hospital Affiliated to Mudanjiang Medical University

  collaborator UNKNOWN

• The Third Affiliated Hospital of Qiqihar Medical University

  collaborator UNKNOWN

• The Baoquanling Hospital of Beidahuang Group

  collaborator UNKNOWN

• Daqing Longnan Hospital, China

  collaborator UNKNOWN

• The First Hospital of Suihua City

  collaborator UNKNOWN

• Jiamusi Central Hospital

  collaborator UNKNOWN

• Beidahuang Industry Group General Hospital

  collaborator OTHER

• The First Affiliated Hospital of Jiamusi University, China

  collaborator UNKNOWN

• Shuangyashan Shuangkuang Hospital

  collaborator UNKNOWN

• Beijing Peking University WBL Biotech Co., Ltd.

  collaborator INDUSTRY

• Hegang People Hospital

  collaborator UNKNOWN

• Harbin Medical University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-03-01

Primary Completion

2028-10-31

Completion

2030-04-30

Countries

• China

Study Locations